Eisai Pharmaceuticals India Pvt. Ltd. (EIL) was incorporated in March 2007. It is a subsidiary of global Japanese pharmaceutical company, Eisai Co., Ltd., based in Tokyo, Japan.
Eisai at a Glance
Over 80 Years of history
Toyoji Naito, Eisai’s founder, established Nihon Eisai Co., Ltd. in 1941, focusing on in-house R&D to create new medicines. ‘Eisai’ (pronounced Ezai) means ‘ei; sanitation, health’ and sai; materials, product’ respectively.
FINANCIAL
FY2023 Revenue
(fiscal year ended March 31, 2024)
741.8 Billion JPY
$4.79 Billion USD
More than 40 subsidiaries
Over 11,000 Employees Worldwide
Over 11,000 employees are working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries with operations in Japan, Americas (North America), China, EMEA (Europe, the Middle East, Africa, Russia and Oceania), and Asia and Latin America.
About Us
EIL’s commercial operations are carried out through its Mumbai office, and its manufacturing and R&D operations are carried out at its integrated facility in Visakhapatnam (Vizag).
Mumbai
Vizag
Our Major Milestones
Incorporation of Eisai Pharmaceuticals India Pvt. Ltd.
Eisai Pharmatechnology and Manufacturing Pvt. Ltd. was established. Laid foundation for the development of State-of-the-Art Facility.
Eisai Knowledge Center, commenced it's operations.
FDA and PMDA regulatory approvals
MHRA and KFDA approvals
Launch of Dayvigo. The innovative first-in-class therapy in insomnia.
Launch of Fycompa & Lenvima. Integration of Multiple Sclerosis Business Unit
Commencement of G-API development for generics. Merger of Indian entities to form Eisai Pharmaceuticals India Pvt. Ltd. (EIL)
Start of new R&D block and early stage development
WHO approvals
Message from Leadership
Dr. Girish Dixit
To download our Annual return of the company Form MGT-7